Immunotherapy for Solid Tumors a Review for Surgeons

download Immunotherapy for Solid Tumors a Review for Surgeons

of 11

Transcript of Immunotherapy for Solid Tumors a Review for Surgeons

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    1/11

    http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018http://www.journalofsurgicalresearch.com/http://www.sciencedirect.com/science/journal/00224804mailto:[email protected]

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    2/11

    http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    3/11

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    4/11

    http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    5/11

    http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    6/11

    http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    7/11

    http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    8/11

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    9/11

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    10/11

    http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018http://refhub.elsevier.com/S0022-4804(13)02196-3/sref90http://refhub.elsevier.com/S0022-4804(13)02196-3/sref90http://refhub.elsevier.com/S0022-4804(13)02196-3/sref90http://refhub.elsevier.com/S0022-4804(13)02196-3/sref90http://refhub.elsevier.com/S0022-4804(13)02196-3/sref90http://refhub.elsevier.com/S0022-4804(13)02196-3/sref89http://refhub.elsevier.com/S0022-4804(13)02196-3/sref89http://refhub.elsevier.com/S0022-4804(13)02196-3/sref89http://refhub.elsevier.com/S0022-4804(13)02196-3/sref88http://refhub.elsevier.com/S0022-4804(13)02196-3/sref88http://refhub.elsevier.com/S0022-4804(13)02196-3/sref88http://refhub.elsevier.com/S0022-4804(13)02196-3/sref88http://refhub.elsevier.com/S0022-4804(13)02196-3/sref88http://refhub.elsevier.com/S0022-4804(13)02196-3/sref87http://refhub.elsevier.com/S0022-4804(13)02196-3/sref87http://refhub.elsevier.com/S0022-4804(13)02196-3/sref87http://refhub.elsevier.com/S0022-4804(13)02196-3/sref86http://refhub.elsevier.com/S0022-4804(13)02196-3/sref86http://refhub.elsevier.com/S0022-4804(13)02196-3/sref86http://refhub.elsevier.com/S0022-4804(13)02196-3/sref86http://refhub.elsevier.com/S0022-4804(13)02196-3/sref85http://refhub.elsevier.com/S0022-4804(13)02196-3/sref85http://refhub.elsevier.com/S0022-4804(13)02196-3/sref85http://refhub.elsevier.com/S0022-4804(13)02196-3/sref85http://refhub.elsevier.com/S0022-4804(13)02196-3/sref85http://refhub.elsevier.com/S0022-4804(13)02196-3/sref85http://refhub.elsevier.com/S0022-4804(13)02196-3/sref84http://refhub.elsevier.com/S0022-4804(13)02196-3/sref84http://refhub.elsevier.com/S0022-4804(13)02196-3/sref84http://refhub.elsevier.com/S0022-4804(13)02196-3/sref83http://refhub.elsevier.com/S0022-4804(13)02196-3/sref83http://refhub.elsevier.com/S0022-4804(13)02196-3/sref83http://refhub.elsevier.com/S0022-4804(13)02196-3/sref82http://refhub.elsevier.com/S0022-4804(13)02196-3/sref82http://refhub.elsevier.com/S0022-4804(13)02196-3/sref82http://refhub.elsevier.com/S0022-4804(13)02196-3/sref82http://refhub.elsevier.com/S0022-4804(13)02196-3/sref81http://refhub.elsevier.com/S0022-4804(13)02196-3/sref81http://refhub.elsevier.com/S0022-4804(13)02196-3/sref81http://refhub.elsevier.com/S0022-4804(13)02196-3/sref81http://refhub.elsevier.com/S0022-4804(13)02196-3/sref80http://refhub.elsevier.com/S0022-4804(13)02196-3/sref80http://refhub.elsevier.com/S0022-4804(13)02196-3/sref80http://refhub.elsevier.com/S0022-4804(13)02196-3/sref80http://refhub.elsevier.com/S0022-4804(13)02196-3/sref79http://refhub.elsevier.com/S0022-4804(13)02196-3/sref79http://refhub.elsevier.com/S0022-4804(13)02196-3/sref79http://refhub.elsevier.com/S0022-4804(13)02196-3/sref79http://refhub.elsevier.com/S0022-4804(13)02196-3/sref78http://refhub.elsevier.com/S0022-4804(13)02196-3/sref78http://refhub.elsevier.com/S0022-4804(13)02196-3/sref78http://refhub.elsevier.com/S0022-4804(13)02196-3/sref77http://refhub.elsevier.com/S0022-4804(13)02196-3/sref77http://refhub.elsevier.com/S0022-4804(13)02196-3/sref77http://refhub.elsevier.com/S0022-4804(13)02196-3/sref77http://refhub.elsevier.com/S0022-4804(13)02196-3/sref76http://refhub.elsevier.com/S0022-4804(13)02196-3/sref76http://refhub.elsevier.com/S0022-4804(13)02196-3/sref76http://refhub.elsevier.com/S0022-4804(13)02196-3/sref76http://refhub.elsevier.com/S0022-4804(13)02196-3/sref75http://refhub.elsevier.com/S0022-4804(13)02196-3/sref75http://refhub.elsevier.com/S0022-4804(13)02196-3/sref75http://refhub.elsevier.com/S0022-4804(13)02196-3/sref75http://refhub.elsevier.com/S0022-4804(13)02196-3/sref75http://refhub.elsevier.com/S0022-4804(13)02196-3/sref74http://refhub.elsevier.com/S0022-4804(13)02196-3/sref74http://refhub.elsevier.com/S0022-4804(13)02196-3/sref74http://refhub.elsevier.com/S0022-4804(13)02196-3/sref74http://refhub.elsevier.com/S0022-4804(13)02196-3/sref74http://refhub.elsevier.com/S0022-4804(13)02196-3/sref74http://refhub.elsevier.com/S0022-4804(13)02196-3/sref73http://refhub.elsevier.com/S0022-4804(13)02196-3/sref73http://refhub.elsevier.com/S0022-4804(13)02196-3/sref73http://refhub.elsevier.com/S0022-4804(13)02196-3/sref73http://refhub.elsevier.com/S0022-4804(13)02196-3/sref72http://refhub.elsevier.com/S0022-4804(13)02196-3/sref72http://refhub.elsevier.com/S0022-4804(13)02196-3/sref72http://refhub.elsevier.com/S0022-4804(13)02196-3/sref72http://refhub.elsevier.com/S0022-4804(13)02196-3/sref71http://refhub.elsevier.com/S0022-4804(13)02196-3/sref71http://refhub.elsevier.com/S0022-4804(13)02196-3/sref71http://refhub.elsevier.com/S0022-4804(13)02196-3/sref70http://refhub.elsevier.com/S0022-4804(13)02196-3/sref70http://refhub.elsevier.com/S0022-4804(13)02196-3/sref69http://refhub.elsevier.com/S0022-4804(13)02196-3/sref69http://refhub.elsevier.com/S0022-4804(13)02196-3/sref69http://refhub.elsevier.com/S0022-4804(13)02196-3/sref69http://refhub.elsevier.com/S0022-4804(13)02196-3/sref68http://refhub.elsevier.com/S0022-4804(13)02196-3/sref68http://refhub.elsevier.com/S0022-4804(13)02196-3/sref68http://refhub.elsevier.com/S0022-4804(13)02196-3/sref67http://refhub.elsevier.com/S0022-4804(13)02196-3/sref67http://refhub.elsevier.com/S0022-4804(13)02196-3/sref67http://refhub.elsevier.com/S0022-4804(13)02196-3/sref67http://refhub.elsevier.com/S0022-4804(13)02196-3/sref67http://refhub.elsevier.com/S0022-4804(13)02196-3/sref66http://refhub.elsevier.com/S0022-4804(13)02196-3/sref66http://refhub.elsevier.com/S0022-4804(13)02196-3/sref66http://refhub.elsevier.com/S0022-4804(13)02196-3/sref66http://refhub.elsevier.com/S0022-4804(13)02196-3/sref65http://refhub.elsevier.com/S0022-4804(13)02196-3/sref65http://refhub.elsevier.com/S0022-4804(13)02196-3/sref64http://refhub.elsevier.com/S0022-4804(13)02196-3/sref64http://refhub.elsevier.com/S0022-4804(13)02196-3/sref64http://refhub.elsevier.com/S0022-4804(13)02196-3/sref63http://refhub.elsevier.com/S0022-4804(13)02196-3/sref63http://refhub.elsevier.com/S0022-4804(13)02196-3/sref63http://refhub.elsevier.com/S0022-4804(13)02196-3/sref62http://refhub.elsevier.com/S0022-4804(13)02196-3/sref62http://refhub.elsevier.com/S0022-4804(13)02196-3/sref62http://refhub.elsevier.com/S0022-4804(13)02196-3/sref62http://refhub.elsevier.com/S0022-4804(13)02196-3/sref61http://refhub.elsevier.com/S0022-4804(13)02196-3/sref61http://refhub.elsevier.com/S0022-4804(13)02196-3/sref61http://refhub.elsevier.com/S0022-4804(13)02196-3/sref61http://refhub.elsevier.com/S0022-4804(13)02196-3/sref61http://refhub.elsevier.com/S0022-4804(13)02196-3/sref60http://refhub.elsevier.com/S0022-4804(13)02196-3/sref60http://refhub.elsevier.com/S0022-4804(13)02196-3/sref60http://refhub.elsevier.com/S0022-4804(13)02196-3/sref59http://refhub.elsevier.com/S0022-4804(13)02196-3/sref59http://refhub.elsevier.com/S0022-4804(13)02196-3/sref59http://refhub.elsevier.com/S0022-4804(13)02196-3/sref58http://refhub.elsevier.com/S0022-4804(13)02196-3/sref58http://refhub.elsevier.com/S0022-4804(13)02196-3/sref58http://refhub.elsevier.com/S0022-4804(13)02196-3/sref57http://refhub.elsevier.com/S0022-4804(13)02196-3/sref57http://refhub.elsevier.com/S0022-4804(13)02196-3/sref57http://refhub.elsevier.com/S0022-4804(13)02196-3/sref57http://refhub.elsevier.com/S0022-4804(13)02196-3/sref57http://refhub.elsevier.com/S0022-4804(13)02196-3/sref57http://refhub.elsevier.com/S0022-4804(13)02196-3/sref56http://refhub.elsevier.com/S0022-4804(13)02196-3/sref56http://refhub.elsevier.com/S0022-4804(13)02196-3/sref56http://refhub.elsevier.com/S0022-4804(13)02196-3/sref55http://refhub.elsevier.com/S0022-4804(13)02196-3/sref55http://refhub.elsevier.com/S0022-4804(13)02196-3/sref55http://refhub.elsevier.com/S0022-4804(13)02196-3/sref55http://refhub.elsevier.com/S0022-4804(13)02196-3/sref54http://refhub.elsevier.com/S0022-4804(13)02196-3/sref54http://refhub.elsevier.com/S0022-4804(13)02196-3/sref53http://refhub.elsevier.com/S0022-4804(13)02196-3/sref53http://refhub.elsevier.com/S0022-4804(13)02196-3/sref52http://refhub.elsevier.com/S0022-4804(13)02196-3/sref52http://refhub.elsevier.com/S0022-4804(13)02196-3/sref52http://refhub.elsevier.com/S0022-4804(13)02196-3/sref52

  • 8/10/2019 Immunotherapy for Solid Tumors a Review for Surgeons

    11/11

    http://dx.doi.org/10.1016/j.jss.2013.12.018http://dx.doi.org/10.1016/j.jss.2013.12.018http://refhub.elsevier.com/S0022-4804(13)02196-3/sref109http://refhub.elsevier.com/S0022-4804(13)02196-3/sref109http://refhub.elsevier.com/S0022-4804(13)02196-3/sref109http://refhub.elsevier.com/S0022-4804(13)02196-3/sref109http://clinicaltrials.gov/NCT01109095http://clinicaltrials.gov/NCT01109095http://clinicaltrials.gov/NCT01140373http://clinicaltrials.gov/NCT01869166http://clinicaltrials.gov/NCT01373047http://clinicaltrials.gov/NCT01373047http://refhub.elsevier.com/S0022-4804(13)02196-3/sref103http://refhub.elsevier.com/S0022-4804(13)02196-3/sref103http://refhub.elsevier.com/S0022-4804(13)02196-3/sref103http://refhub.elsevier.com/S0022-4804(13)02196-3/sref103http://refhub.elsevier.com/S0022-4804(13)02196-3/sref103http://refhub.elsevier.com/S0022-4804(13)02196-3/sref102http://refhub.elsevier.com/S0022-4804(13)02196-3/sref102http://refhub.elsevier.com/S0022-4804(13)02196-3/sref102http://refhub.elsevier.com/S0022-4804(13)02196-3/sref102http://refhub.elsevier.com/S0022-4804(13)02196-3/sref102http://clinicaltrials.gov/NCT01621490http://clinicaltrials.gov/NCT01621490http://clinicaltrials.gov/NCT01629758http://clinicaltrials.gov/NCT01658878http://clinicaltrials.gov/NCT01420965http://clinicaltrials.gov/NCT00112580http://clinicaltrials.gov/NCT00112580http://clinicaltrials.gov/NCT01804465http://clinicaltrials.gov/NCT01804465http://clinicaltrials.gov/NCT01008358http://clinicaltrials.gov/NCT01008358http://clinicaltrials.gov/NCT01655888http://clinicaltrials.gov/NCT01445379http://refhub.elsevier.com/S0022-4804(13)02196-3/sref92http://refhub.elsevier.com/S0022-4804(13)02196-3/sref92http://refhub.elsevier.com/S0022-4804(13)02196-3/sref92http://refhub.elsevier.com/S0022-4804(13)02196-3/sref91http://refhub.elsevier.com/S0022-4804(13)02196-3/sref91http://refhub.elsevier.com/S0022-4804(13)02196-3/sref91http://refhub.elsevier.com/S0022-4804(13)02196-3/sref91

Tumour immunology I - StudentVIP · 2018. 2. 23. · Tumour immunology II Immunotherapy Origin of immunotherapy: Tumour immunotherapy: Preventative immunotherapy – anti-viral vaccines-Many

Tumour immunology I - StudentVIP · 2018. 2. 23. · Tumour immunology II Immunotherapy Origin of immunotherapy: Tumour immunotherapy: Preventative immunotherapy – anti-viral vaccines-Many

Immunotherapy and Gene Therapy of Cancer1cancerres.aacrjournals.org/content/canres/51/18...IMMUNOTHERAPY AND GENE THERAPY OF CANCER Table 1 Immunotherapy of murine tumors with IL-2

Immunotherapy and Gene Therapy of Cancer1cancerres.aacrjournals.org/content/canres/51/18...IMMUNOTHERAPY AND GENE THERAPY OF CANCER Table 1 Immunotherapy of murine tumors with IL-2

Immune biomarkers in thymic epithelial tumors: expression ......quently associated with B1 and B2 subtypes, in particular myasthenia gravis. Immunotherapy may be a promising option

Immune biomarkers in thymic epithelial tumors: expression ......quently associated with B1 and B2 subtypes, in particular myasthenia gravis. Immunotherapy may be a promising option

Powerful, Tumor-agnostic Immunotherapy Treatment · 2020. 8. 20. · destroy the cancer cells. Instead of cytotoxic agents, use the body’s own immune system against tumors. Immunotherapy

Powerful, Tumor-agnostic Immunotherapy Treatment · 2020. 8. 20. · destroy the cancer cells. Instead of cytotoxic agents, use the body’s own immune system against tumors. Immunotherapy

Cellular Immunotherapy for Malignant Brain Tumors...for Malignant Brain Tumors Catherine Flores and Duane A. Mitchell Duke Brain Tumor Immunotherapy Program Duke University USA 1.

Cellular Immunotherapy for Malignant Brain Tumors...for Malignant Brain Tumors Catherine Flores and Duane A. Mitchell Duke Brain Tumor Immunotherapy Program Duke University USA 1.

Immunotherapy for gliomas: shedding light on progress in ...moonlab/ewExternalFiles/78-Garcia...Gliomas are histologically highly heterogeneous tumors and malignant glioma represent

Immunotherapy for gliomas: shedding light on progress in ...moonlab/ewExternalFiles/78-Garcia...Gliomas are histologically highly heterogeneous tumors and malignant glioma represent

Targeting Cold Tumors with Immunotherapy: Focus on GI ...

Targeting Cold Tumors with Immunotherapy: Focus on GI ...

INVESTOR PRESENTATION - Lytix Biopharmalytixbiopharma.com/uploads/Lytix Biopharma - Company presentation... · 4 the main challenge in cancer immunotherapy is to turn cold tumors

INVESTOR PRESENTATION - Lytix Biopharmalytixbiopharma.com/uploads/Lytix Biopharma - Company presentation... · 4 the main challenge in cancer immunotherapy is to turn cold tumors

Advances in the Immunotherapy of Solid Tumors Malignant Melanoma (8 minutes)

Advances in the Immunotherapy of Solid Tumors Malignant Melanoma (8 minutes)

Mixed immunotherapy and chemotherapy of tumors: …depillis/REPRINTS/DePillisGuRadJTB20… · mathematical model of Kirschner and Panetta (1998), which also focuses on the tumor–immune

Mixed immunotherapy and chemotherapy of tumors: …depillis/REPRINTS/DePillisGuRadJTB20… · mathematical model of Kirschner and Panetta (1998), which also focuses on the tumor–immune

Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into ...

Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into ...

Clinical Response of a Patient to Anti PD-1 Immunotherapy ...Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors Shalin Shah1, James E.Ward1,2, Riyue Bao2, Curtis

Clinical Response of a Patient to Anti PD-1 Immunotherapy ...Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors Shalin Shah1, James E.Ward1,2, Riyue Bao2, Curtis

Phenotypic characterization of human colorectal cancer stem cells · CA 94305; **Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, 20133 Milano, Italy; and ††Department

Phenotypic characterization of human colorectal cancer stem cells · CA 94305; **Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, 20133 Milano, Italy; and ††Department

Immunotherapy in head and neck cancer and MSI in solid tumors

Immunotherapy in head and neck cancer and MSI in solid tumors

Gene expression studies of breast tumors with different responses to immunotherapy

Gene expression studies of breast tumors with different responses to immunotherapy

Immunity and Tumors Cancer Immunotherapy. Immunity and Tumors 1890s Coley treats patients with bacterial extracts 1950-1960s Burnet and Thomas- Immune-surveillance.

Immunity and Tumors Cancer Immunotherapy. Immunity and Tumors 1890s Coley treats patients with bacterial extracts 1950-1960s Burnet and Thomas- Immune-surveillance.

Advances in Cancer Immunotherapy for Solid Tumors Prospects in Solid Tumor...Advances in Cancer Immunotherapy for Solid Tumors. Expert Perspectives on The New Data. Sunday, June 5,

Advances in Cancer Immunotherapy for Solid Tumors Prospects in Solid Tumor...Advances in Cancer Immunotherapy for Solid Tumors. Expert Perspectives on The New Data. Sunday, June 5,

Advances in Cancer Immunotherapy for Solid Tumors in Immunotherapy... · 2016-06-10 · Advances in Cancer Immunotherapy for Solid Tumors. Expert Perspectives on The New Data. Sunday,

Advances in Cancer Immunotherapy for Solid Tumors in Immunotherapy... · 2016-06-10 · Advances in Cancer Immunotherapy for Solid Tumors. Expert Perspectives on The New Data. Sunday,

Computational Health Informatics Program, Boston Children ... · associated with improved immunotherapy response 15. 12/57 NSCLC tumors with high TMB had at least one tumor region

Computational Health Informatics Program, Boston Children ... · associated with improved immunotherapy response 15. 12/57 NSCLC tumors with high TMB had at least one tumor region

Wasp and Bee Venom Immunotherapy Immunotherapy Department

Wasp and Bee Venom Immunotherapy Immunotherapy Department